TOPLINE:

In an Italian study involving more than 900 patients with chronic rhinosinusitis with nasal polyps (CRSwNP), dupilumab reduced NP scores and alleviated nasal obstruction at 2 years. Over 91% of patients had a good-to-excellent response, with approximately 19% successfully extending treatment intervals to every 4 weeks.

METHODOLOGY:

• Researchers conducted an observational study of 926 patients (median age, 54 years; 61.4% men) with severe, uncontrolled CRSwNP to assess the effectiveness and safety of dupilumab.
• All patients self-administered 300 mg subcutaneous dupilumab and were divided into group A (n = 753) with 2-week dosing and group B (n = 173) with 4-week dosing; symptom changes were then compared between the groups.
• A good-to-excellent response to dupilumab corresponded to a score of 4 in normosmic patients and 3 in those without comorbidities.

TAKEAWAY:

• The median NP score decreased significantly from 6 at baseline to 1 at 24 months, and the median score on the nasal obstruction visual analog scale dropped from 8 to 1 (P < .0001 for both).
• At 24 months, 91.2% of patients achieved a good-to-excellent response.
• Nearly 19% of patients extended their dupilumab dosing interval to every 4 weeks over the 2 years, and no significant differences in clinical outcomes were observed between the groups.
• Treatment was discontinued due to adverse events in 2.4% of patients, primarily due to arthralgia (0.6%) and persistent eosinophilia with asthma exacerbation (0.4%).

IN PRACTICE:

“[The study] results contribute to the growing evidence supporting dupilumab’s role as a cornerstone therapy for severe CRSwNP,” the authors wrote. 

SOURCE:

Eugenio De Corso, MD, PhD, with A. Gemelli University Hospital Foundation IRCCS, Rome, Italy, was the corresponding author of the study, which was published online on August 30, 2025 in Allergy.

LIMITATIONS:

The absence of a control group, retrospective data collection, and inclusion of only Italian participants may have limited generalizability. The proposed criteria for disease control and remission were not validated or standardized through consensus-based guidelines.

DISCLOSURES:

Several authors reported receiving lecture fees from and participating in expert board meetings for various pharmaceutical companies. 

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.